Takeaway

• Empagliflozin improved symptoms, physical limitations (PLS), and quality of life (QoL) in patients hospitalized for acute heart failure (HF), with benefits persisting through 90 days.
• Furthermore, the benefits of empagliflozin were not influenced by the degree of symptomatic impairment at baseline.

Why this matters

• Acute HF is characterized by...